Latest Derivatives News

Page 4 of 69
LinQ Minerals has identified more than 429 metres of visually mineralised core at a new target south of Gidginbung, although laboratory assays are still pending. The ASX-listed explorer also reported broad copper-gold results at Monza, fresh gold hits at Gidginbung and A$14.4 million in cash to fund its next drilling phase.
Maxwell Dee
Maxwell Dee
27 Oct 2026
Arovella has released two clinical batches of its off-the-shelf CAR-iNKT therapy, activated two trial sites and begun screening patients ahead of expected first dosing in October. The biotech ended September with A$11.6 million in cash, rising to about A$15.63 million pro forma after an R&D rebate.
Ada Torres
Ada Torres
23 Oct 2026
DeSoto Resources has expanded its Timbakouna power auger program by 200 holes after airborne geophysics generated new targets across Guinea’s Siguiri Basin. The company ended September with A$7.74 million in cash, while initial drilling assays are expected in early November.
Maxwell Dee
Maxwell Dee
22 Oct 2026
Patagonia Lithium has completed its latest Cilon drilling campaign with Well 8 delivering 2,043 litres per hour and rapid aquifer recovery, while a corrected estimate put the pumped lithium at a preferred 30kg. The result now feeds into a resource upgrade, but a disappointing Well 9 infill hole adds uncertainty about aquifer continuity.
Maxwell Dee
Maxwell Dee
22 Oct 2026
Tasmea delivered record FY26 earnings and lifted its FY27 guidance, as the WorkPac acquisition reshaped the group and the newly completed Maxim and JPS deals move into the numbers. The opportunity is substantial, but so is the execution task: margin mix, integration and earn-out obligations now matter more than ever.
Victor Sage
Victor Sage
19 Oct 2026
Hazer Group has expanded its commercial pipeline through a paid Japanese utility study assessing hydrogen facilities of up to 300,000 tonnes per year, while its KBR alliance advances a standardised commercial-scale design. The company ended September with A$8.3 million in cash and reported A$12.9 million in pro-forma funding, but remains pre-revenue in the quarter.
Victor Sage
Victor Sage
19 Oct 2026
Noxopharm has completed its first-in-human safety trial for SOF-SKN and advanced the wider Sofra platform, but its annual report flags a material uncertainty over funding. The biotech ended June with A$293,573 in cash, net liabilities of A$3.65 million and a need for additional capital.
Ada Torres
Ada Torres
16 Oct 2026
Alara Resources’ independently audited reserve statement supports about eight more years of production at its Oman copper mine, with 7.70 million tonnes classified as Probable Ore Reserves. The update also reveals the limits of the mine plan: the licence expires before the scheduled mine life ends, while several technical studies remain unfinished.
Maxwell Dee
Maxwell Dee
14 Oct 2026
Lion Rock Minerals has reported repeated shallow heavy-mineral zones with significant monazite at Minta Est, including up to 1.94% estimated TREO and 3.62% calculated monazite in recovered concentrate. Early magnetic-separation tests also concentrated up to 84.1% of calculated TREO into less than 27% of recovered heavy-mineral mass, although the results remain preliminary and HMC-based.
Maxwell Dee
Maxwell Dee
14 Oct 2026
Cauldron Energy has completed a 10,506-metre Yanrey drilling campaign that extended mineralisation at Manyingee South and Manyingee North, including a link towards Paladin’s neighbouring Manyingee deposit. The ASX-listed uranium explorer now plans to fold the results into a JORC resource update expected within two months, while a visit from Uzbekistan’s Navoiyuran adds a separate potential development thread.
Maxwell Dee
Maxwell Dee
6 Oct 2026
DevEx has recorded uranium-equivalent intersections at Nabarlek North and mapped kilometre-scale alteration along the Nabarlek Fault Corridor. The results strengthen the company’s exploration pipeline, but laboratory assays and further drilling are still needed to establish the significance of the early readings.
Maxwell Dee
Maxwell Dee
6 Oct 2026
Neurotech International has moved NTI164 into a registration-enabling Phase III autism trial, but its annual report carries a material going-concern warning. The company says post-year-end debt and equity funding should support the program through topline data, subject to execution and completion.
Ada Torres
Ada Torres
5 Oct 2026

Browse the archive

Full archive